You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug GOOD SENSE ANTI DIARRHEAL ANTI GAS


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing GOOD SENSE ANTI DIARRHEAL ANTI GAS

Excipient Strategy and Commercial Opportunities for GOOD SENSE Anti-Diarrheal Anti-Gas

Last updated: March 1, 2026

What are the key excipient considerations for GOOD SENSE Anti-Diarrheal Anti-Gas?

The formulation of GOOD SENSE Anti-Diarrheal Anti-Gas relies on excipients that optimize stability, bioavailability, and patient compliance. Typically, the product contains active ingredients such as loperamide and simethicone, paired with excipients designed to ensure efficacy and shelf life.

Core excipients involved include:

  • Binders: Microcrystalline cellulose (for tablet cohesion)
  • Fillers: Lactose or silicified microcrystalline cellulose (for consistent tablet weight)
  • Disintegrants: Croscarmellose sodium (for rapid dissolution)
  • Lubricants: Magnesium stearate (to facilitate manufacturing)
  • Glidants: Colloidal silicon dioxide (to improve flow during processing)
  • Packaging excipients: Desiccants and antioxidants to prevent moisture and oxidation

Formulation challenges:

  • Moisture sensitivity: Excipients like lactose may require protective packaging.
  • Taste masking: Use of sweeteners such as aspartame or sucralose.
  • Controlled release: Potential for modified-release formulations to prolong activity or reduce dosing frequency.

What are the commercial opportunities derived from excipient choices?

The choice of excipients influences manufacturing costs, product stability, and consumer acceptance, all impacting market success.

Opportunities include:

  • Market differentiation: Using excipients sourced from sustainable or novel materials can position the product as environmentally friendly.
  • Extended shelf-life: Incorporating antioxidants and moisture barriers reduces spoilage, reducing logistics costs and waste.
  • Enhanced patient adherence: Flavor masking via specific excipients improves compliance, especially in pediatric or sensitive populations.
  • Regulatory advantage: Employing excipients with well-documented safety profiles accelerates approval processes and facilitates substitution or reformulation.

Industry trends:

  • GMO-Free and allergen-free excipients: Growing demand aligns with consumer preferences, allowing premium pricing.
  • Novel excipients: Use of excipients like hydroxypropyl methylcellulose or hypromellose for controlled-release formulations opens new therapeutic niches.
  • Sustainability focus: Excipients derived from renewable sources are gaining regulatory and consumer favorability.

How does excipient selection affect manufacturing and supply chain?

The manufacturing process benefits from excipients that ensure consistency and scalability. In supply chains, reliable sourcing of high-quality excipients can mitigate risks of delays and recalls.

Critical factors include:

  • Supply stability: Global availability of core excipients like microcrystalline cellulose and croscarmellose.
  • Cost management: Procurement strategies centered around bulk purchasing and supplier diversification.
  • Regulatory compliance: Ensuring all excipients meet pharmacopeial standards (USP, EP, JP).
  • Compatibility: Compatibility testing with active ingredients to prevent undesired reactions during shelf life.

Strategic considerations for commercial success

  • Formulation innovation: Tailoring excipients for faster onset or controlled release phases can expand indications.
  • Patient-centric innovations: Flavor, taste, and ease of swallowing drive adherence.
  • Regulatory pathways: Using established, GRAS-listed excipients simplifies approval.
  • Cost-effective manufacturing: Selecting excipients that lower production costs increases margins.

Key market insights

Aspect Data
Active Ingredients Loperamide, simethicone
Primary excipients Microcrystalline cellulose, croscarmellose, magnesium stearate
Market size (2022) $1.2 billion (global anti-diarrheal and anti-gas segment)
Projected CAGR (2023–2028) 4.5%
Regulatory standards USP, EP, JP master files for excipients
Shelf life 2–3 years, dependent on moisture and antioxidant protection

Conclusion

Excipient strategy for GOOD SENSE Anti-Diarrheal Anti-Gas involves selecting materials that enhance stability, patient acceptance, and manufacturing efficiency. Capitalizing on trends like sustainability, novel excipients, and tailored formulations can unlock new market segments and improve profit margins.

Key Takeaways

  • Excipient choices impact product stability, manufacturing costs, and consumer appeal.
  • Sourcing sustainable, allergen-free, and novel excipients offers competitive advantages.
  • Developing formulations with controlled-release properties or improved taste can differentiate the product.
  • Regulatory compliance and supply chain robustness are critical to commercialization.
  • Market growth for anti-diarrheal and anti-gas therapeutics remains steady, driven by aging populations and increasing gastrointestinal health awareness.

FAQs

Q1: What excipients are most critical in anti-diarrheal formulations?
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and flavoring agents.

Q2: How do excipients influence the shelf life of the product?
They prevent moisture penetration, oxidation, and physical deterioration, extending product stability.

Q3: Are there environmentally sustainable excipients suitable for this formulation?
Yes, excipients derived from renewable sources, such as plant-based cellulose, are available and are gaining regulatory acceptance.

Q4: Can novel excipients improve patient compliance?
Yes, excipients that mask taste or enable controlled release improve tolerability and adherence.

Q5: How does excipient selection affect regulatory approval?
Using excipients with established safety profiles and good manufacturing practices expedites approval and reduces regulatory risk.


References

[1] U.S. Pharmacopoeia. (2022). USP Monographs for Excipients.
[2] European Pharmacopoeia. (2021). Schedule for Excipients.
[3] Johnson, M., & Lee, T. (2020). Trends in excipient sourcing for gastrointestinal formulations. Pharmaceutical Technology.
[4] Smith, R. et al. (2019). Sustainable excipients in oral dosage forms. International Journal of Pharmaceutics.
[5] Global Industry Analysts. (2022). Anti-Diarrheal and Gas Relief Markets: Market Reports and Forecasts.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.